<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01347333</url>
  </required_header>
  <id_info>
    <org_study_id>08-045</org_study_id>
    <nct_id>NCT01347333</nct_id>
  </id_info>
  <brief_title>Stereotactic Body Radiotherapy for Liver Tumors</brief_title>
  <official_title>Phase IV Trial Evaluating the Use of Stereotactic Body Radiotherapy for the Treatment of Liver Metastases and Primary Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mercy Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mercy Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the local control rate as well as acute and late toxicity rates of
      stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary
      liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single site, non-randomized, prospective, phase IV trial.

      Composed of 4 patient groups:

        1. Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm

        2. Metastases from neuroendocrine tumors with functional endocrine syndromes

        3. Unresectable hepatocellular carcinoma (HCC)

        4. Unresectable intrahepatic cholangiocarcinoma (IHCC) Data collected will include patient
           demographics, pathology data, tumor stage, SBRT dose fractionation scheme, dose received
           by adjacent critical normal tissues, tumor recurrence data, and acute and late
           toxicities. Follow up data will be collected during the patient's standard office
           visits. The anticipated duration of this study is 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>local control rate</measure>
    <time_frame>5 years</time_frame>
    <description>Primary endpoint will be local tumor recurrence rate. Local recurrence is defined as tumor recurrence within the planning target volume. Local control rate will be evaluated by imaging techniques, physical exam and biopsy, if applicable. If necessary, a PET/CT scan may be used to aid in the diagnoses of local tumor recurrence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>late complication rates</measure>
    <time_frame>5 years</time_frame>
    <description>Toxicities will be assessed using CTCAE grading criteria at specified timepoints.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Liver Metastases</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>liver metastases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm Metastases from neuroendocrine tumors with functional endocrine syndromes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Primary Liver Tumors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Hepatocellular Carcinoma Intrahepatic Cholangiocarcinoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic body radiosurgery</intervention_name>
    <description>36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)</description>
    <arm_group_label>liver metastases</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiotherapy</intervention_name>
    <description>26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)</description>
    <arm_group_label>Primary Liver Tumors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age &gt;= 18 years

          -  Zubrod performance status of 0-3

          -  Oligometastases (1-3) with aggregate tumor diameter &lt; 6 cm

          -  Metastases from neuroendocrine tumors with functional endocrine syndromes for symptom
             palliation

          -  Unresectable hepatocellular carcinoma (HCC)

          -  Unresectable intrahepatic cholangiocarcinoma (IHCC)

          -  Maximum tumor diameter &lt; 6 cm

          -  Adequate liver function:

        Total bilirubin &lt; 3 mg/dL Serum albumin &gt; 2.5 g/dL Serum levels of liver enzymes &lt; 3 times
        the upper limit of normal Normal PT and PTT unless patient is receiving anticoagulant
        medication

        - Signed study-specific consent form

        Exclusion Criteria:

          -  Maximum tumor diameter &gt; 6 cm

          -  Prior radiotherapy to the liver

          -  Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown
             effects of RT on lactating females

          -  Patients with psychiatric or addictive disorder that would preclude obtaining informed
             consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bethany G Sleckman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mercy Hospital St. Louis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. John's Mercy Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2011</study_first_submitted>
  <study_first_submitted_qc>May 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2011</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mercy Research</investigator_affiliation>
    <investigator_full_name>Kathy Baglan, MD</investigator_full_name>
    <investigator_title>Radiation Oncologist</investigator_title>
  </responsible_party>
  <keyword>liver metastases</keyword>
  <keyword>stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

